Excalium
← Live feed
Company · News
Simulations Plus — stock news & what’s moving it
2 recent stories tracked by Excalium
Simulations Plus Q3 revenue up 7% to $21.9M; services revenue up 20%; net income $3.6M
Jul 9, 2026 · The strong growth in services revenue indicates robust demand for specialized drug development solutions, while the flat
Simulations Plus advances drug development with NVIDIA BioNeMo Agent Toolkit
Jun 23, 2026 · Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit Yahoo Finance
Part of the
Excalium
live feed — every business, tech & financial story that might move the stocks you own.